Ozempic Linked to Drop in Violent Behavior in Rutgers Study
🤖 AI Generated ImageA Rutgers University study published this week in the journal Criminology found something researchers describe as their strongest result: among current GLP-1 users, the well-established link between impulsivity and violent behavior was substantially weaker. Not eliminated. Weaker — by about 62%.
The drugs being studied were Ozempic and Wegovy. The finding was not expected.
What the Rutgers Study Actually Measured
The research team, led by Daniel Semenza, director of research at the New Jersey Gun Violence Research Center at the Rutgers School of Public Health, analyzed data from a 2025 nationally representative survey of 7,521 U.S. adults.
They focused on 821 individuals who had ever used a GLP-1 medication, including 597 currently taking one.
Participants answered questions about their impulsivity, alcohol use, and — with guaranteed confidentiality — violent acts committed in the past year, assessed using a validated self-reported offending scale covering fighting, assault, and robbery.
The key comparison was between current and former users. Among former GLP-1 users, high impulsivity and heavy alcohol use strongly predicted violent behavior — consistent with decades of existing criminology research.
Among current users, those same risk factors were significantly muted. According to Newswise's coverage of the Rutgers announcement, the impulsivity-violence link was 62% weaker and the alcohol-violence link was 52% weaker in active users.
📰 Related: Ozempic May Fight Addiction Too — Massive Study of 600,000 Veterans Finds Results
🤖 AI Generated ImageThe Cognitive Behavioral Therapy Comparison
Christopher Thomas, an assistant professor at Rutgers who co-authored the study, offered the most striking framing of the findings: GLP-1 drugs appear to work like cognitive behavioral therapy — not by eliminating impulsivity or anger, but by weakening the direct path from impulse to action.
CBT teaches patients to pause between feeling an urge and acting on it. The researchers found that GLP-1 medications appear to produce a pharmacological version of that pause.
The brain still generates the impulse. The medication appears to reduce how readily that impulse becomes behavior.
According to Neuroscience News, the mechanism may involve GLP-1 receptors in the brain's reward and impulse-control pathways — distinct from the metabolic pathways that drive weight loss. These drugs were originally developed for diabetes.
Their effects on brain circuitry are now the subject of separate research programs entirely.
📰 Related: GLP-1 Drugs: The Promises and the Troubling Side Effects Nobody Told You About
What the Study Cannot Prove
Semenza has been explicit about the limitations. The study is observational and cross-sectional — it captures a snapshot in time, not a before-and-after comparison in the same individuals.
The design cannot prove that starting a GLP-1 drug causes a reduction in violent behavior.
People who take GLP-1 medications may differ from those who do not in ways the survey did not capture. The sample size of active users — 597 people — is large enough to detect a signal, not large enough to rule out confounding.
Semenza described the finding as a first step, not a final answer. Randomized controlled trials tracking violent behavior as an outcome measure in GLP-1 users have not been conducted.
📰 Related: Ozempic Users Are Moving Less, Not More — New Fitbit Study Finds
🤖 AI Generated ImageA Drug Prescribed for Weight Loss Is Becoming Something Else
GLP-1 receptor agonists were approved for type 2 diabetes. They became a global phenomenon for weight loss. In the past 18 months, peer-reviewed research has linked them to reductions in alcohol dependency, depression, anxiety, and now — tentatively — violent behavior.
Each new finding adds a dimension the original clinical trials were not designed to detect. The drugs are now being used by millions globally. Novo Nordisk's Wegovy pill reached more than 3 million prescriptions since January 2026, according to ScienceDaily's coverage of the Rutgers findings.
Whether the behavioral effects are consistent, durable, and safe across diverse populations remains unanswered. But the question is now serious enough to have landed in one of criminology's leading journals.
Key Takeaways
- A Rutgers University study published in Criminology analyzed data from 7,521 U.S. adults, focusing on 821 GLP-1 users (597 currently taking one).
- Among current GLP-1 users, the impulsivity-violence link was 62% weaker and the alcohol-violence link was 52% weaker than among former users.
- Lead researcher Daniel Semenza (New Jersey Gun Violence Research Center) described the drugs as potentially working like cognitive behavioral therapy — weakening the path from impulse to action.
- The study is observational and cross-sectional — it cannot prove causation and calls for randomized controlled trial follow-up.
- GLP-1 drugs have now been linked in peer-reviewed research to reduced alcohol dependency, depression, anxiety, and violent behavior — all beyond their original diabetes indication.
- Novo Nordisk's Wegovy pill has exceeded 3 million prescriptions since January 2026.
Sources
Also Read
Health & Science Correspondent
Dr. Chris Farley brings a medical background to his reporting on healthcare policy, scientific research, and global health developments. He makes complex medical news easy to understand.
